586412-88-6

Basic information

• Product Name: tert-butyl 4-(3-nitrophenoxy)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(3-nitrophenoxy)piperidine-1-carboxylate
• CAS NO: 586412-88-6
• Molecular Formula: C₁₆H₂₂N₂O₅
• Molecular Weight: 322.35628
• Mol File: 586412-88-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-(3-nitrophenoxy)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-nitrophenoxy)piperidine-1-carboxylate(586412-88-6)
• EPA Substance Registry System: tert-butyl 4-(3-nitrophenoxy)piperidine-1-carboxylate(586412-88-6)

Safety Data

• Hazardous Substances Data: 586412-88-6(Hazardous Substances Data)

Upstream product

• 554-84-7 meta-nitrophenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 591-27-5 m-Hydroxyaniline 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 402-67-5 3-fluoro-1-nitrobenzene 

Downstream Products

• 586412-89-7 4-(3- nitrophenoxy)piperidine 
• 871032-54-1 6-methyl-N-[3-(4-piperidinyloxy)phenyl]-4'-(trifluoromethoxy)-[1,1'-biphenyl]-2-carboxamide 
• 790667-68-4 tert-butyl 4-(3-aminophenoxy)piperidine-1-carboxylate 

Relevant articles and documents

Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)

c-KIT kinase is a validated drug discovery target for gastrointestinal stromal tumors (GISTs). Clinically used c-KIT kinase inhibitors, i.e., Imatinib and Sunitinib, bear other important targets such as ABL or FLT3 kinases. Here we report our discovery of

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.

Pyrimidine derivative, preparation method therefor and application thereof in medicine

The invention relates to a pyrimidine derivative, a preparation method therefor and an application thereof in medicine. Particularly, the invention relates to a compound as shown in general formula (M) or a stereisomer, an aquo-complex, a metabolic product, a solvate, a pharmaceutically acceptable salt, a co-crystallization or a prodrug thereof; the preparation method thereof; and the application of the medicine composition thereof and the compound medicine compound in the medicine, particularly the application as an EGFR target spot inhibitor, wherein the definition of each substituent group in the general formula (M) is the same as that of the specification.